High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor.
AIDS
; 24(3): 467-9, 2010 Jan 28.
Article
em En
| MEDLINE
| ID: mdl-19996935
ABSTRACT
Mutations H358Y, L363F/M, A364V and A366T/V confer in-vitro resistance to bevirimat. Moreover, polymorphisms at the Glutamine-Valine-Threonine (QVT) motif (369-371) have been associated with reduced bevirimat activity in vivo. The rate of these changes was assessed in 389 HIV+ patients naïve for bevirimat. QVT polymorphisms were frequent (47%), especially in non-B subtypes (93%). Conversely, only four patients (1%) harbored major bevirimat resistance mutations. Finally, specific gag changes were associated with protease inhibitor resistance mutations in subtype B viruses.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Polimorfismo Genético
/
Succinatos
/
Triterpenos
/
HIV-1
/
Fármacos Anti-HIV
/
Farmacorresistência Viral Múltipla
Idioma:
En
Ano de publicação:
2010
Tipo de documento:
Article